Qin Yu

Qin has over 15 years of drug discovery and development experience. She previously was the Senior Director of Viral Therapeutics at Ascidian Therapeutics and the Director of Platform Technology at Rubius Therapeutics.

Qin brings her extensive R&D experience with gene therapy vectors and red blood cell-based therapy to Carmine. She most recently served as the Senior Director at Ascidian Therapeutics, leading the in vitro and in vivo Proof of Concept research for a novel gene therapy platform.

Prior to that Qin was the Director of Platform Technology at Rubius Therapeutics, building the team from the ground up and leading the Red Cell Therapeutics platform and early programs to successful IND submissions.

Qin’s industry career started on leading antiviral drug discovery teams and projects at a biotech and later at Novartis and AstraZeneca. She received her Ph.D. in Microbiology from the University of Alabama at Birmingham. Her postdoctoral training was completed at the Salk Institute for Biological Studies.